Heidelberg, Germany, 15.05.2019 – PROGEN Biotechnik GmbH, established manufacturer of premium antibodies, has announced the succession of its former General Manager Dr. Sven Kuhlendahl who died last November. Since April first, Katja Betts and Maik Lander have been leading the company as equals.
Katja Betts holds an EMSc in Communications Management and a BA (Hons) in Communications. She has gathered management experience in the life science sector at the non-profit organization EMBO and while working as European Marketing Manager for a laboratory equipment distributor. As Head of Marketing she has been responsible for PROGEN’s focus on new markets since 2016 and has been instrumental in expanding the company’s international business during this time.
Ms. Betts is looking forward to the new tasks ahead: “Our focus in the near future will be on the development of existing and new markets in collaboration with international partners.”
Maik Lander holds a graduate degree in Biotechnology and Chemical Technology Engineering. His academic education was followed by many years of experience in process development in biotechnology manufacturing, amongst others at ReliaTech GmbH, a specialist growth factors and antibodies.
In 2016 he joined PROGEN as Head of Production and is now committed to the responsibilities ahead: “We will concentrate on novel, customer-oriented product developments that provide a competitive edge in protein detection, quantification and purification.”
Maik Lander and Katja Betts both worked closely with former General Manager Sven Kuhlendahl and intend to continue the successful management of the thriving company in joint leadership ‒ together with an excellent and tight-knit team. In these new roles, Ms. Betts will primarily oversee all market-relevant areas while Mr. Lander will assume responsibilities for the entire product development and manufacturing process.